Neurocrine Bio. (NBIX) PT Lowered to $115 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $145.79 -0.05%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
UBS analyst Ashwani Verma lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $115.00 (from $121.00) while maintaining a Buy rating.
You May Also Be Interested In
- Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
- PrairieSky Royalty Ltd (PSK:CN) (PREKF) PT Raised to Cdn$38.75 at CIBC
- West Fraser Timber Co Ltd (WFG:CN) (WFTBF) PT Raised to Cdn$101 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
